Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

(2021) Hope S Rugo et al.   LANCET ONCOLOGY

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

(2021) Rebecca Dent et al.   BREAST CANCER RESEARCH AND TREATMENT

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

(2021) Christopher Sweeney et al.   LANCET

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

(2021) Nicholas Turner et al.   BREAST CANCER RESEARCH AND TREATMENT

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

(2020) Robert H Jones et al.   LANCET ONCOLOGY

Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

(2020) Lillian M Smyth et al.   CLINICAL CANCER RESEARCH

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

(2020) Seth A. Wander et al.   Cancer Discovery

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)†

(2020) F. Cardoso et al.   ANNALS OF ONCOLOGY

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

(2020) Nicholas C Turner et al.   LANCET ONCOLOGY

Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

(2020) Simon J. Crabb et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4 /6 Inhibitor Therapy

(2020) Madeline M. Cook et al.   ONCOLOGIST

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

(2020) F. André et al.   ANNALS OF ONCOLOGY

Genomic characterization of metastatic breast cancers

(2019) François Bertucci et al.   NATURE

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer

(2019) Carlotta Costa et al.   Cancer Discovery

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

(2019) Peter Schmid et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic Functional Annotation of Somatic Mutations in Cancer

(2018) Patrick Kwok-Shing Ng et al.   CANCER CELL

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

(2018) Pedram Razavi et al.   CANCER CELL

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

(2018) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) José Baselga et al.   LANCET ONCOLOGY

Maximising the potential of AKT inhibitors as anti-cancer treatments

(2017) Jessica S. Brown et al.   PHARMACOLOGY & THERAPEUTICS

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2

(2016) Gabriel N. Hortobagyi et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†

(2014) M. Piccart et al.   ANNALS OF ONCOLOGY

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

(2014) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

(2012) B. R. Davies et al.   MOLECULAR CANCER THERAPEUTICS

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH